-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the journal Thoracic Cancer published the results of a phase II clinical study from Japan, mainly to evaluate the efficacy of Pembrolizumab (pembrolizumab) as a single agent in the first-line treatment of elderly NSCLC with high PD-L1 expressi.
Recently, the journal Thoracic Cancer published the results of a phase II clinical study from Japan, mainly to evaluate the efficacy of Pembrolizumab (pembrolizumab) as a single agent in the first-line treatment of elderly NSCLC with high PD-L1 expressi.
This multicenter, open-label, single-arm Phase II study was conducted at 12 institutio.
This multicenter, open-label, single-arm Phase II study was conducted at 12 institutio.
The study included 26 patients with a median age of 78 years (range 75-90 year.
The median PFS was 6 months (95% CI 1-2
A total of 14% of patients experienced grade 3, 4, or 5 adverse even.
A total of 14% of patients experienced grade 3, 4, or 5 adverse even.
In conclusion, the study shows that pembrolizumab (pembrolizumab) is effective and tolerable in the first-line treatment of elderly NSCLC with high PD-L1 expressi.
In conclusion, the study shows that pembrolizumab (pembrolizumab) is effective and tolerable in the first-line treatment of elderly NSCLC with high PD-L1 expressi.
Original source:
Original source:Masuda T, Fujitaka K,Suzuki T, Hamai K, Matsumoto N, Matsumura M, et .
Masuda T, Fujitaka K,Suzuki T, Hamai K, Matsumoto N, Matsumura M, et .
Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small-cell lung cancer expressing high PD-L Thorac Canc.
202 https://d.
org/11111/1759-7711442 Leave a message here
